Market Research Logo

Marburg Hemorrhagic Fever - Pipeline Review, H2 2015

Marburg Hemorrhagic Fever - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Marburg Hemorrhagic Fever - Pipeline Review, H2 2015’, provides an overview of the Marburg Hemorrhagic Fever’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Marburg Hemorrhagic Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Marburg Hemorrhagic Fever and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Marburg Hemorrhagic Fever
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Marburg Hemorrhagic Fever and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Marburg Hemorrhagic Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Marburg Hemorrhagic Fever pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Marburg Hemorrhagic Fever
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Marburg Hemorrhagic Fever pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Marburg Hemorrhagic Fever Overview
Therapeutics Development
Pipeline Products for Marburg Hemorrhagic Fever - Overview
Pipeline Products for Marburg Hemorrhagic Fever - Comparative Analysis
Marburg Hemorrhagic Fever - Therapeutics under Development by Companies
Marburg Hemorrhagic Fever - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Marburg Hemorrhagic Fever - Products under Development by Companies
Marburg Hemorrhagic Fever - Companies Involved in Therapeutics Development
Arbutus Biopharma Corporation
Crucell N.V.
GlaxoSmithKline Plc
Immunovaccine, Inc.
Integrated BioTherapeutics, Inc.
Sarepta Therapeutics, Inc.
Marburg Hemorrhagic Fever - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AVI-7288 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ebola [strain sudan, zaire] + marburg vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
marburg vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
marburg vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies for Ebola and Marburg Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody for Marburg Virus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
panfilovirus (multivalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TKM-Marburg - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Marburg Hemorrhagic Fever - Recent Pipeline Updates
Marburg Hemorrhagic Fever - Dormant Projects
Marburg Hemorrhagic Fever - Product Development Milestones
Featured News & Press Releases
Jul 22, 2015: Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplus platform
Feb 10, 2014: Sarepta Therapeutics Announces Positive Safety Results from Phase I Clinical Study of Marburg Drug Candidate
Nov 12, 2013: Tekmira Announces New Preclinical Data On TKM-Marburg
Oct 08, 2013: Tekmira Provides Corporate Update On RNAi Therapeutics Product TKM-Marburg
Sep 25, 2013: Tekmira Presents New Anti-Viral Efficacy Data Against the Marburg Hemorrhagic Fever Virus
May 07, 2013: Sarepta Therapeutics Initiates Dosing In Phase I Multiple Ascending Dose Study Of Drug For Treatment Of Marburg Virus
Mar 04, 2013: Sarepta Therapeutics's Marburg Drug Shows High Survival Rates After Intramuscular Delivery In Non-Human Primates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Marburg Hemorrhagic Fever, H2 2015
Number of Products under Development for Marburg Hemorrhagic Fever - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Marburg Hemorrhagic Fever - Pipeline by Arbutus Biopharma Corporation, H2 2015
Marburg Hemorrhagic Fever - Pipeline by Crucell N.V., H2 2015
Marburg Hemorrhagic Fever - Pipeline by GlaxoSmithKline Plc, H2 2015
Marburg Hemorrhagic Fever - Pipeline by Immunovaccine, Inc., H2 2015
Marburg Hemorrhagic Fever - Pipeline by Integrated BioTherapeutics, Inc., H2 2015
Marburg Hemorrhagic Fever - Pipeline by Sarepta Therapeutics, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Marburg Hemorrhagic Fever Therapeutics - Recent Pipeline Updates, H2 2015
Marburg Hemorrhagic Fever - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for Marburg Hemorrhagic Fever, H2 2015
Number of Products under Development for Marburg Hemorrhagic Fever - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report